Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Industry Insights

Science and business issues impacting the China biotech industry...

Arbor, a US Gene Editing Company, Raises $215 Million Led by Singapore, Hong Kong, US Investors

Week in Review: Sanofi Acquires Kadmon, a US-China Pharma, for $1.9 Billion

Shanghai Offers Financial Support for Novel Drugs, Devices and Services

China Cross-Border Life Science Deals Get 2021 Off to a Fast Start

ChinaBio® Report: 2020 China Life Science Investment Hits New Records

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China